Research programme: gene editing therapeutics - Intellia Therapeutics/Regeneron Pharmaceuticals/SparingVision
Latest Information Update: 14 Oct 2022
At a glance
- Originator Intellia Therapeutics; SparingVision
- Class Gene therapies
- Mechanism of Action Gene modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Unspecified
Most Recent Events
- 04 Aug 2022 Early research in Unspecified (Parenteral) (Intellia Therapeutics pipeline, September 2022)
- 01 Jun 2020 Regeneron and Intellia Therapeutics expands existing collaboration to provide Regeneron with rights to develop products for the treatment of Haemophilia A and B
- 15 Mar 2017 Intellia Therapeutics files for patent protection for Lipid nanoparticle delivery technology